EQ Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 44
- Market Cap
- $36.8M
- Website
- http://www.equilliumbio.com
- Introduction
EQ Inc is a provider of digital marketing services. It operates in a single segment, which is to provide real-time technology and advanced analytics to improve performance for web, mobile, social, and video advertising initiatives and focuses on targeted advertising and incorporates advertising technologies, data analytics, and programmatic media buying capabilities into a single segment. EQ's geographical segments are Canada and the United States, of which the vast majority of its revenue comes from Canada. It generates the highest revenue from Advertising Services, followed by Data sales, which includes fixed CPM data and licenses.
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
- Conditions
- Alopecia AreataAlopeciaAlopecia TotalisAlopecia Universalis
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Equillium
- Target Recruit Count
- 36
- Registration Number
- NCT05589610
- Locations
- 🇦🇺
Sinclair Dermatology, East Melbourne, Australia
🇦🇺Fremantle Dermatology, Fremantle, Australia
🇦🇺Premier Specialists, Kogarah, Australia
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
- Conditions
- GVHDGraft Versus Host DiseaseAcute-graft-versus-host DiseaseAcute GVHDaGVHD
- Interventions
- Drug: EQ001 Placebo
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Equillium
- Target Recruit Count
- 158
- Registration Number
- NCT05263999
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
- Conditions
- Coronavirus
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Equillium
- Registration Number
- NCT04605926
- Locations
- 🇨🇴
Inv Site CO01, Medellín, Colombia
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
- Conditions
- Lupus ErythematosusLupus Nephritis
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Equillium
- Target Recruit Count
- 52
- Registration Number
- NCT04128579
- Locations
- 🇺🇸
AKDHC Medical Research Services, LLC, Sun City, Arizona, United States
🇺🇸California Institute of Renal Research, Chula Vista, California, United States
🇺🇸University of California San Diego Perlman Ambulatory Clinic, La Jolla, California, United States
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Equillium
- Target Recruit Count
- 18
- Registration Number
- NCT04007198
- Locations
- 🇦🇺
Flinders Medical Centre, Adelaide, Australia
🇦🇺Box Hill Hospital, Box Hill, Australia
🇦🇺Monash Medical Centre, Clayton, Australia
- Prev
- 1
- 2
- Next
News
Global Clinical Trials Landscape for Alopecia Universalis Reveals Growing Research Activity Across Major Pharmaceutical Companies
A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types.
Itolizumab Shows Promising Results in Phase 2 Ulcerative Colitis Trial, Matching Adalimumab Efficacy
Itolizumab demonstrated a 23.3% clinical remission rate in moderate to severe ulcerative colitis patients after 12 weeks, comparable to adalimumab's 20.0% and superior to placebo's 10.0%.
Vivtex and Equillium Collaborate on Oral Biologic for GI Inflammation
Vivtex and Equillium have entered a research agreement to develop an oral formulation of EQ302, a bispecific peptide therapy targeting IL-15 and IL-21.